LEGN logo

LEGEND BIOTECH CORP-ADR

LEGNNASDAQ
πŸ† #1021 by market capEarnings Aug 11 Β· PreUS Equity
$21.83β–² $1.21 (+5.56%)
Live
1hβ€”
24hβ–² 5.6%
7dβ–² 14.1%
14dβ–² 14.7%
30dβ–Ό 19.4%
1yβ–Ό 39.7%
🏦Market Cap
$8.11B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+56.4%
High Growth
πŸ“ŠGross Margin
55.0%
Healthy
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
4.2x
Fair
Otter Score
54
Weak

Trading Snapshot

Day Range
$21.52 – $22.22
52-Week Range
$16.24 – $45.30
Volume
$2.31B
Avg Volume
$1.80B
Shares Outstanding
371.5M
Next Earnings
Oct 23, 2026

Fundamentals Snapshot

Annual Revenue
$1.14B
Last Q Revenue
$311M
P/E Ratio
β€”
P/S Ratio
4.2x
EPS (TTM)
$-0.68
Dividend Yield
β€”

Why Investors Own LEGN

  • βœ“High-growth profile β€” revenue up -9.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 31% gross margin and 30% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$1.14Bβ–Ό βˆ’12.5% YoY
Gross Margin (TTM)
31.2%β–² +3.5% YoY
Operating Income (TTM)
$310Mβ–Ό βˆ’12.5% YoY
Free Cash Flow (TTM)
$338Mβ–Ό βˆ’12.5% YoY

About LEGEND BIOTECH CORP-ADR

A company profile for LEGEND BIOTECH CORP-ADR isn’t available yet β€” check back soon.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
54/100

Analyst Ratings

β“˜
Consensus
Buy
23 analysts
Strong Buy7
Buy11
Hold5
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

SeekingAlphaΒ·6h ago

Legend Biotech Corporation 2026 Q2 - Results - Earnings Call Presentation

2026-08-11. The following slide deck was published by Legend Biotech Corporation in conjunction with their 2026 Q2 earnings call.

SeekingAlphaΒ·9h ago

Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call August 11, 2026 8:00 AM EDTCompany ParticipantsCaroline LeCates PaulAlan Bash - Interim CEO &...

🌌
BenzingaΒ·16h ago

Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate

Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 147.06 percent increase over losses of $(0.34) per share from the

SeekingAlphaΒ·1d ago

Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

GileadҀ™s 2026 outlook improves as R&D pipeline accelerates and Biktarvy & Livdelzi sales rise, lifting guidance.

BenzingaΒ·7d ago

Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold players in this sector.

SeekingAlphaΒ·12d ago

Bristol-Myers Squibb: Why I'm Still Bullish After Q2

Bristol-Myers Squibb Company hits a 52-week high on Q2 results, EPS guidance raise, and key drugsҀ™ momentum. Read why BMY stock is a buy.